Dan Nomura

Haha I would never…

This paper now out in ACS Central Science!! pubs.acs.org/doi/10.1021/...

Awesome to be back in Cambridge for #ChemBiointhePub ahead of the Bioorganic Chemistry GRC!

Our latest paper w/ @pottslab.bsky.social & @amgen.bsky.social in @jacs.acspublications.org by co-first authors @cmzammit.bsky.social & Cory Nadel on discovery of covalent destabilizing degrader of AR & AR-V7 in prostate cancer. Thanks also to @themarkfdn.bsky.social ! pubs.acs.org/doi/10.1021/...

Excited to announce a new collaboration between the Molecular Therapeutics Initiative (MTI) and Amgen Inc.! This partnership includes funding for cutting-edge research & an internship program for grad students to train in drug discovery & development at Amgen.
#MTI #Amgen #Biotech #UCB

Spirit Preliminary score: ND

Bioorganic GRC is set! I got tired of the lack of swag so made a couple of unofficial tees. Order one if you want to support the conference (or simply enjoy strange looks in grocery stores).

Spirit: chembio-shop.fourthwall.com/products/grc...

World Tour: chembio-shop.fourthwall.com/products/spi...

Cocrystal structure reveals the mechanism of FSP1 inhibition by FSEN1 | PNAS FSP1 is an FAD-dependent oxidoreductase that uses NAD(P)H to regenerate the reduced forms of lipophilic quinone antioxidants, such as coenzyme Q10 ...

Thrilled this paper is out! We solved the first cocrystal structure of FSP1 with an inhibitor (FSEN1), providing mechanistic insight & a foundation for medchem. Led by Amalia Megarioti & Sitao Zhang. A terrific collaboration with Da Jia.
Brief Skytorial!
1/9

Congrats to chem bio grad students Ellie King, Lauren Orr, and Vienna Thomas on graduating with their PhD's!

Our 2025 lab photo!

- Mutations mimicking glues by @brianliau.bsky.social al and Ning Zheng
- Covalent and bivalent glue engagement by @dannomura.bsky.social, Nathanael Gray, @georgwinter.bsky.social and @alessiociulli.bsky.social
- And finish it of with a discussion on general mode-of-action.

Excited that our work revealing the structure and function of the monster stress response silencing factor, the E3 ligase SIFI, is now out! Congratulations to the most amazing team of Zhi Yang, Diane Haakonsen, Michael Heider and Sam Witus!

www.nature.com/articles/s41...

How to stop the shift of drug discovery from the U.S. to China U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb explains how to stop the shift.

www.statnews.com/2025/05/06/h...

New-preprint alert! We use chemoproteomic profiling to show MYST KAT inhibitors exhibit hierarchical target engagement (KAT6A/B > KAT7 >> KAT8). Reminiscent of Type I kinase inhibitors, the selectivity of these small molecules varies based on concentration.

www.biorxiv.org/content/10.1...

Thanks to @olzmannlab.bsky.social for the great collaboration, and also thanks to @novartis.bsky.social @themarkfdn.bsky.social

DCAF16-Based Covalent Degradative Handles for the Modular Design of Degraders Targeted protein degradation (TPD) is a powerful strategy for targeting and eliminating disease-causing proteins. While heterobifunctional Proteolysis-Targeting Chimeras (PROTACs) are more modular, th...

Excited to highlight our latest preprint by graduate student Lauren Orr on the discovery of a covalent degradative handle that acts through two unique C173 and C178, on the E3 ligase DCAF16 that can be used to modularly design monovalent and bifunctional degraders.

www.biorxiv.org/content/10.1...

On my way to #aacr25. I’ll be chairing Part 3 of “Chemistry to the Clinic” tomorrow (4/26 at 2:30) with talks from @dannomura.bsky.social and @xiaoyuzhang.bsky.social. Weather report calls for lots of chemoproteomics, molecular glues, and tough targets. Please join us!

Excited to moderate a panel at the @theaacr.bsky.social CICR townhall at #2025AACR on "Charting the Course: Innovating Cancer Drug Discovery in a Challenging Landscape" alongside Shiva Malek, Gwenn Hansen, Ryan Schoenfeld, and Joseph Pearlberg!

Back in Chicago for #2025AACR! I’ll be giving a talk on our latest work tomorrow in the Educational Session on Advances in Ligand Discovery to Enable Previously Intractable Targets on Sat Apr 26th 2:30-4:00pm in S406 McCormick South alongside @michael-erb.bsky.social & @xiaoyuzhang.bsky.social !

Amazing talk yesterday by @rushika-perera.bsky.social for our Molecular Therapeutics seminar series!

Had such an awesome time at @themarkfdn.bsky.social symposium today!!

Amazing Quality Control Life Processes conference in Frankfurt organized by @idikic.bsky.social !! Great science, great friends!

Cool paper from Woo lab: https://www.biorxiv.org/content/10.1101/2025.03.24.645050v1

Mimicry of molecular glues using dual covalent chimeras - Nature Communications The authors report the development of dual covalent proximity inducing molecules capable of selectively cross-linking two non-interacting proteins. Through the selective proximity-based activation of ...

Cool paper from Rullo lab: www.nature.com/articles/s41...

A Bivalent Molecular Glue Linking Lysine Acetyltransferases to Oncogene-induced Cell Death Developing cancer therapies that induce robust death of the malignant cell is critical to prevent relapse. Highly effective strategies, such as immunotherapy, exemplify this observation. Here we provi...

Cool paper from Crabtree and Gray labs:

www.biorxiv.org/content/10.1...

graph of NIH basisfor new drugs

A pie graph worth keeping in mind as the NIH budget plummets jamanetwork.com/journals/jam... for 356 new FDA drugs approved

Proteome-Wide Discovery of Degradable Proteins Using Bifunctional Molecules Targeted protein degradation (TPD) is an emergent therapeutic strategy with the potential to circumvent challenges associated with targets unamenable to conventional pharmacological inhibition. Among ...

Cool paper from Parker lab: www.biorxiv.org/content/10.1...

Amazing meeting last week in Germany: 130th International Titisee Conferences on Stress Signalling in Development and Disease organized by Brenda Schulman & @micharapelab.bsky.social !

Discovery of a VHL molecular glue degrader of GEMIN3 by Picowell RNA-seq Targeted protein degradation (TPD) is an emerging therapeutic modality in which small molecules are used to recruit targets to the natural protein degradation machinery of the cell. Molecular glue deg...

🚨 Rational discovery of VHL molecular glues. New Preprint from @amgen.bsky.social Induced Proximity group led by postdoc Jonathan Bushman reports the discovery of a VHL molecular glue degrader of GEMIN3 by Picowell RNA-seq. Read on for details. 🧵1/8 www.biorxiv.org/content/10.1...

https://www.latimes.com/california/story/2025-03-19/university-of-california-hiring-freeze-budget-trump-funding-cuts

https://www.thedp.com/article/2025/03/penn-trump-freezes-federal-funding-sports